JMDC Inc.: history, ownership, mission, how it works & makes money

Founded on January 31, 2002 in Tokyo, JMDC Inc. has transformed from a medical statistics service into a healthcare data powerhouse that has issued 5 million IDs through its Pep Up platform and assembled anonymized receipt and examination records for over 10 million people, serving health insurers, pharmaceutical firms and research institutions; with a capital stock of ¥25,134 million, a workforce of 488, and strategic shareholders like OMRON, the company reported a 36.5% year-on-year revenue jump to ¥41,722 million for FY March 31, 2025, posted a first-half FY2026 revenue rise of 24.4% and operating profit up 27.7%, and holds a market capitalization of ¥245.64 billion as of December 12, 2025-evidence of how its dual pillars, Health Big Data and Telemedicine, monetize anonymized datasets, analytics, platform services and telehealth solutions while targeting full-year revenue of ¥50,500 million and operating profit of ¥11,500 million for FY2026, positioning JMDC at the intersection of data-driven health promotion and scalable healthcare solutions.

JMDC Inc. (4483.T): Intro

• Founded on January 31, 2002 in Tokyo, Japan, as a medical statistics/data-service company serving payers and providers.
• 2008 - Expanded to data provision and aggregation services for health insurance associations and local-government health services, beginning large-scale claims and health-check data partnerships.
• 2012 - Launched the Pep Up health-data platform and issued more than 5 million individual IDs to enable personal health-promotion services and linkage of longitudinal records.
• 2014 - Built a healthcare big-data repository combining anonymized receipt (claims) and examination data for over 10 million people; began serving pharmaceutical companies, insurers, and academic researchers.
• 2019 - Merged with subsidiary cotree Co., Ltd., integrating an online counseling/mental-health platform into JMDC's product set to broaden digital-health services.
• 2024 - Transferred shares of NOAH MEDICAL SYSTEM CORPORATION to sharpen focus on core JMDC operations and improve profitability metrics.

• Publicly listed on the Tokyo Stock Exchange (ticker: 4483.T); corporate governance follows J-SOX and TSE disclosure rules.
• Shareholder base: mix of founder/insider ownership, major Japanese trust banks and institutional investors, and retail investors. Institutional holdings typically include large trust banks and asset managers (e.g., The Master Trust Bank of Japan and other custodian/trust arrangements commonly seen among top shareholders).
• Corporate group: operating subsidiaries for data services, analytics, platform products (Pep Up, cotree-origin services), and specialized data licensing businesses; periodic divestments (e.g., NOAH share transfer in 2024) to refocus resources.

• Mission: Leverage large-scale, anonymized health data to improve population health, reduce medical costs, and accelerate research and development across healthcare stakeholders.
• Vision: Create a data-driven healthcare ecosystem where longitudinal claims, checkup, and behavioral data enable preventive care, evidence-based planning, and digital-health services.
• Strategic pillars: expand data coverage and linkages; build subscription and platform revenues; service pharma, insurers and local governments; and scale direct-to-user health-promotion products.

• Data acquisition: Aggregates anonymized claims (receipt) data, health-check/examination records, and other payer/provider sources via contracts with health insurers, employer-based plans and municipalities.
• De-identification & governance: Applies privacy-preserving linkage keys and governance controls to create research-ready datasets while complying with Japanese privacy law and industry best practice.
• Platform stack:
  • Pep Up: consumer-facing health ID and engagement layer (5M+ issued IDs since launch in 2012).
  • Claims & examination DB: longitudinal resource created in 2014 with over 10 million persons' anonymized records; continually expanded thereafter.
  • Analytics & SaaS: dashboards, benchmark tools, risk stratification models, and custom analytics for payers, pharma and local governments.
• Professional services: consulting, study support, and bespoke data extracts/cohort creation for clinical research and outcomes assessment.

• Data licensing & analytics subscriptions - recurring revenue from pharmaceutical companies, contract research organizations (CROs), insurers and research institutions licensing de-identified cohorts and analytics tools.
• Platform & SaaS fees - subscription-based access to dashboards, benchmarking, population-health management and payer tools (typically enterprise contracts with multi-year terms).
• Professional services & custom projects - one-off fees for bespoke analyses, research support, health-promotion program design and local-government projects.
• Consumer & B2C services - Pep Up and allied services for individuals (engagement, wellness programs), with monetization via partnerships and value-added services.
• Partnerships & collaborations - joint initiatives with insurers, municipalities and healthcare providers that may include revenue-sharing (e.g., prevention program outcomes-based contracts).

• Pharmaceutical R&D: real-world evidence (RWE) cohort generation, treatment-pattern analysis, safety and pharmacoepidemiology studies.
• Insurers & employers: population health management, risk stratification, cost-driver identification, and evaluation of prevention programs.
• Local governments: health-check aggregation, lifestyle-disease surveillance, and support for regional health-promotion policy.
• Academic & clinical research: provision of de-identified datasets for observational studies and health-services research.

• Longitudinal claims linkage capability supporting multi-year trend analysis.
• Established privacy/de-identification processes suitable for commercial research and regulatory-grade outputs.
• Integrated digital-health offerings (Pep Up, cotree-origin counseling) enabling both B2B and B2C engagement pathways.

JMDC Inc. (4483.T): History

• Capital stock (as of March 31, 2025): ¥25,134 million
• Employees: 488
• Major shareholder & strategic partner: OMRON Corporation
• Major customers: health insurance unions, pharmaceutical companies, research institutions

• Data aggregation: collects de-identified insurance claims, health checkup and pharmacy data from health insurance societies and other payers.
• Analytics & SaaS: subscription fees for platforms that provide population health analytics, risk stratification and care-management tools to insurers and employers.
• Research & RWE services: fee-for-service contracts with pharmaceutical companies and research institutions for real-world evidence studies and post-marketing surveillance.
• Licensing & partnerships: strategic collaborations (e.g., with OMRON) for device-data integration, co-developed solutions and licensing of data products.

JMDC Inc. (4483.T): Ownership Structure

• Mission: Promote health for everyone and make better healthcare a reality through medical big data and ICT.
• Social focus: Address increasing medical expenditures, regional care gaps, and medical labor shortages.
• Workplace values: Build a company employees and their families can be proud of; foster a positive work environment.
• Shareholder policy: Balance returns with strategic reinvestment-dividend increases in recent years reflect this stance.

• Data services: Aggregation and anonymization of claims, prescription, and health checkup data to create large-scale datasets for analysis.
• SaaS and analytics: Subscription and license fees for platforms used by insurers, employers, providers, and pharma for utilization management, disease management, and R&D support.
• Solution projects: Customized consulting, predictive models, and program implementation for clients aiming to reduce costs and improve outcomes.
• Partnerships & research: Collaborative contracts with public institutions, payers, and life‑science companies that monetize access to analytics and cohort identification.

• Shareholder balance: mix of institutional investors, corporate partners, and individual shareholders common to Japanese mid‑caps; board and executive team emphasize data governance and compliance.
• Capital allocation: ongoing investments in R&D and M&A to expand data assets and product lineup, alongside gradual increases in dividend payouts to share profits with investors.

JMDC Inc. (4483.T): Mission and Values

• Founded: mid-2000s; headquartered in Tokyo.
• Primary focus: creation and utilization of anonymized healthcare claims and clinical data to drive research, product development and operational improvement across healthcare stakeholders.
• Public listing: Tokyo Stock Exchange (ticker 4483.T).

• Two operating segments: Health Big Data and Telemedicine. These segments convert proprietary and partner-held healthcare data into recurring revenue services and platforms.
• Revenue drivers: subscription/contract fees for data services, analytics and database access; project fees for bespoke analysis; platform fees and transaction revenue from telemedicine and remote image diagnosis services.
• Data governance: builds anonymized claim and PHR (personal health record) databases from health insurance union data and other partner sources, applying de-identification and QA to enable research and industrial use.

• Data aggregation: JMDC collects claims and health checkup data from health insurance associations, employer groups and clinical partners to create longitudinal, anonymized patient-level datasets.
• Product offerings:
  • Medical data analysis services for payers and policy research (utilization patterns, disease burden, cost drivers).
  • Personal Health Record (PHR) services enabling individuals and employers to view aggregated health metrics.
  • Medicine and pharmacy databases used by pharmaceutical companies and medical institutions for market research and safety surveillance.
  • Medical factoring and analytic contracting for hospitals and clinics (revenue cycle, performance benchmarking).
• Scientific and industrial use: the anonymized database is licensed for epidemiological studies, health economics and outcomes research (HEOR), and AI model training.

• Remote image diagnosis: infrastructure and matching services to connect medical images with radiologists / specialists for off-site reading; JMDC supplies the platform and workflow orchestration.
• Telehealth platforms: online counseling and remote consultation services integrated into corporate health packages, improving access to mental health and primary care for employee populations.
• Integration model: JMDC bundles telemedicine access into employer health solutions and payer programs, often combining PHR insights with teleconsultation to create closed-loop care pathways.

• Database licensing: recurring access fees for anonymized datasets to pharma, academia and government agencies.
• Analytics services: paid studies, custom analytics and HEOR projects billed on a project or retainer basis.
• Platform subscriptions: employers and payers subscribe to PHR, care-management and telemedicine platforms.
• Transaction and usage fees: per-visit or per-reading fees for telemedicine and remote image diagnosis services.
• Value-added services: consulting, medical factoring, and integration/support services drive higher-margin revenue.

• Longitudinal coverage - ability to link claims and checkup data over time to measure outcomes and costs.
• Data breadth - medicines, diagnoses, procedures, laboratory and basic PHR data enable multifaceted analytics.
• Compliance and security - de-identification standards and governance frameworks to allow external research while protecting privacy.
• Platform integration - combining analytics with telehealth and employer services to create sticky, multi-product customers.

• Payer analytics: a health insurance union subscribes to benchmarking and cost-driver analytics to manage prescription and hospitalization costs.
• Pharma HEOR: a pharmaceutical company licenses anonymized claim cohorts to support real-world evidence for regulatory filings and market access.
• Employer health program: a corporate client uses PHR + telemedicine to reduce absenteeism and provide mental health counseling to employees.

JMDC Inc. (4483.T): How It Works

• Core customer segments: health insurance associations and unions, local government health services, medical institutions, pharmaceutical companies, research organizations and corporate wellness programs.
• Primary offerings: data provision (raw and aggregated), analytic tools, solution development, medical factoring, publication support and health-promotion services (Pep Up).
• Key data assets: anonymized receipt and examination data covering over 10 million individuals; Pep Up platform with more than 5 million issued IDs.

• Data aggregation: JMDC aggregates claims and examination data from insured populations, standardizes and anonymizes it to create longitudinal datasets that support cohort analyses, epidemiology and drug-utilization studies.
• Licensing & subscriptions: Pharmaceutical and research clients purchase dataset access, periodic extracts or bespoke cohorts under licensing agreements; health insurers and governments subscribe to analytics/SaaS tools for ongoing monitoring and intervention planning.
• Project and consulting fees: Customized analytics, publication support and solution development generate one-off or multi-phase consulting income.
• Pep Up and engagement monetization: The Pep Up health platform - having issued over 5 million IDs - drives recurring fees from program sponsors (insurers, employers, municipalities) and increases the company's first-party longitudinal data capture.
• Medical institution services: Medical factoring, medicine databases and analysis services provide another recurring/transactional revenue stream from clinics and hospitals.

• Scale of data: Large, longitudinal datasets increase the value of licensed extracts and reproducibility of studies, enabling premium pricing for uniquely comprehensive cohorts.
• Recurring revenue mix: Subscription SaaS contracts (insurers, governments) and platform fees (Pep Up) create predictable cash flow, supplemented by variable consulting and project income.
• Cross-selling: Combining Pep Up engagement data with claims/exam datasets enables enriched products for pharma and public-health clients.
• Regulatory and privacy posture: Robust anonymization and compliance are essential to retain institutional clients and enable exports of analytic outputs.

JMDC Inc. (4483.T): How It Makes Money

• Core revenue drivers: data licensing, analytics subscriptions, SaaS platforms, consulting services, and partnerships with pharmaceutical and insurance firms.
• Monetization model: recurring subscription fees for platform access, per-project consulting/analysis fees, and long-term licensing agreements for anonymized claims data.
• Strategic moves: refocusing on core operations after transfer of NOAH MEDICAL SYSTEM CORPORATION shares; continued investment in talent and technology to expand services built on medical big data.

• Customer segments: health insurers, municipalities, hospitals, pharmaceutical companies, and research institutions.
• Product cadence: ongoing enhancement of analytics APIs, disease-specific modules, and expansion of real-world evidence (RWE) services to drive higher ARPU and longer contract durations.
• Investment priorities: hiring specialists in data science and healthcare, upgrading cloud infrastructure, and developing new AI-driven offerings to broaden addressable market.